结合肿瘤生物学来选择省略放射治疗的患者。

IF 2.4 4区医学 Q3 ONCOLOGY Surgical Oncology Clinics of North America Pub Date : 2023-10-01 DOI:10.1016/j.soc.2023.05.006

Lior Z. Braunstein MD

引用次数: 1

摘要

虽然辅助乳腺放射治疗长期以来一直是保乳治疗（BCT）的普遍组成部分，但现在很明显，“癌症”是一个广泛的类别，包括许多不同的疾病，具有不同的自然病史和风险特征。反过来，一些保乳患者在单独手术后会获得非常有利的结果。正在进行的试验试图确定这种低风险患者群体，假设一些人可以安全地放弃放射治疗。上一代试验侧重于风险分层的临床病理特征，而当代研究则采用分子生物标志物来识别那些不太可能从放疗中显著获益的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Surgical Oncology Clinics of North America 医学-外科

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

12 months

期刊介绍： Published four times each year—January, April, July, and October—Surgical Oncology Clinics of North America updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in surgical oncology, including pancreatic cancer, radiation oncology, breast cancer, colorectal cancer, head and neck cancer, palliative care, gene therapy, sarcomas, cancer screening, treatment of colorectal cancer, biliary tract and primary liver tumors, breast cancer, imaging, and more.

期刊最新文献

Contents Anatomy and Embryology of the Anus Epidemiology of Anal Cancer Management of Localized and Locally Advanced Anal Cancer Anal Cancer